English: *(1)Preliminary data derived from a random group of patients with initial MMSE scores between 17 and 22. A 3rd party formal study is being conducted to measure and compare the Ashby Method™ to a placebo group.
(2)Wolfson C, Oremus M, Shukla V et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clinical Therapeutics. 2002 Jun;24(6):862-86; discussion 837.
Abstract Conclusion: The efficacy data indicate that both donepezil and rivastigmine can delay cognitive impairment and deterioration in global health for at least 6 months in patients with mild to moderate AD. Patients receiving active treatment will have more favorable ADAS-cog scores for at least 6 months, after which their scores will begin to converge with those of patients receiving placebo. Differences in methodology, types of direct or indirect costs included, and sources of cost data made it difficult to compare and synthesize findings of the economic studies; therefore, the cost-effectiveness data are inconclusive.
(2)Takeka A, Loveman E, Clegg A, Kirby J et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International Journal of Geriatric Psychiatry. 2006 Jan;21(1):17-28.
Abstract Conclusion: The cholinesterase inhibitors donepezil, rivastigmine, and galantamine can delay cognitive impairment in patients with mild to moderately-severe AD for at least 6 months duration.
(3)Han L, Cole M, Bellavance F et al. Tracking Cognitive Decline in Alzheimer's Disease Using the Mini-Mental State Examination: A Meta-analysis. International Psychogeriatrics. 2000 Jun;12(2):231-47.
Abstract Conclusion: A pooled average estimate of ARC in AD patients was 3.3 points (95% CI: 2.9-3.7) on the MMSE. Significant heterogeneity of ARC estimates existed across the studies and cannot be explained by the study or population characteristics investigated. Effect size of ARC was related to the initial MMSE score of the study population and the number of assessments.
This work has been released into the public domain by its author, Cashby82 at English Wikipedia. This applies worldwide. In some countries this may not be legally possible; if so: Cashby82 grants anyone the right to use this work for any purpose, without any conditions, unless such conditions are required by law.Public domainPublic domainfalsefalse
Original upload log
The original description page was here. All following user names refer to en.wikipedia.
2008-01-25 20:46 Cashby82 1003×768× (84295 bytes) *(1)Preliminary data derived from a random group of patients with initial MMSE scores between 17 and 22. A 3rd party formal study is being conducted to measure and compare the Ashby Method™ to a placebo group. *(2)Wolfson C, Oremus M, Shukla V et al.
2008-01-25 18:43 Cashby82 687×398× (35605 bytes) (1)Preliminary data derived from a random group of patients with initial MMSE scores between 17 and 22. A 3rd party formal study is being conducted to measure and compare the Ashby Method™ to a placebo group. (2)Wolfson C, Oremus M, Shukla V et al. D
Captions
Add a one-line explanation of what this file represents
{{BotMoveToCommons|en.wikipedia|year={{subst:CURRENTYEAR}}|month={{subst:CURRENTMONTHNAME}}|day={{subst:CURRENTDAY}}}} {{Information |Description={{en|*(1)Preliminary data derived from a random group of patients with initial MMSE scores between 17 and 22
File usage
No pages on the English Wikipedia use this file (pages on other projects are not listed).
Metadata
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.
If the file has been modified from its original state, some details may not fully reflect the modified file.